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c-Jun N-terminal kinase (JNK) signaling contributes 
to functional plasticity in the brain and cognition. 
Accumulating evidence implicates a role for MAP ki-
nase kinase 7 (MAP2K7), a JNK activator encoded by 
the Map2k7 gene, and other JNK pathway components in 
schizophrenia (ScZ). Mice haploinsufficient for Map2k7 
(Map2k7+/− mice) display ScZ-relevant cognitive deficits, 
although the mechanisms are unclear. Here we show that 
Map2k7+/− mice display translationally relevant alterations 
in brain function, including hippocampal and mesolimbic 
system hypermetabolism with a contrasting prefrontal 
cortex (PFC) hypometabolism, reminiscent of patients 
with ScZ. In addition Map2k7+/− mice show alterations 
in functional brain network connectivity paralleling those 
reported in early ScZ, including PFC and hippocampal 
hyperconnectivity and compromised mesolimbic system 
functional connectivity. We also show that although the 
cerebral metabolic response to ketamine is preserved, 
the response to dextroamphetamine (d-amphetamine) is 
significantly attenuated in Map2k7+/− mice, supporting 
monoamine neurotransmitter system dysfunction but not 
glutamate/NMDA receptor (NMDA-R) dysfunction as a 
consequence of Map2k7 haploinsufficiency. These effects 
are mirrored behaviorally with an attenuated impact of 
d-amphetamine on sensorimotor gating and locomotion, 
whereas similar deficits produced by ketamine are pre-
served, in Map2k7+/− mice. In addition, Map2k7+/− mice 
show a basal hyperactivity and sensorimotor gating deficit. 
Overall, these data suggest that Map2k7 modifies brain and 
monoamine neurotransmitter system function in a manner 
relevant to the positive and cognitive symptoms of ScZ.
Key words:  network science/preclinical models/ 
functional brain imaging
Introduction
c-Jun N-terminal kinase (JNK) signaling plays a key role 
in synaptic plasticity and neuronal communication.1 In 
humans, mutations in JNK genes lead to intellectual disa-
bility.2 We have identified a common variant in the MAP2K7 
gene (encoding MAP kinase kinase 7 (MAP2K7), which 
activates JNKs) that shows a strong association with schiz-
ophrenia (ScZ).3 Genes in this signaling pathway are inde-
pendently associated with ScZ (supplementary figure S1).4,5 
Hence, strong evidence implicates the pathways modulated 
by MAP2K7 in ScZ. Furthermore, MAP2K7 transcript 
levels are reduced in the prefrontal cortex (PFC) of ScZ 
patients3 and Map2k7 haploinsufficient mice (Map2k7+/− 
mice) show deficits in PFC-dependent tasks.3,6 Despite 
these observations we have a poor understanding of how 
MAP2K7 mutations increase the risk of developing ScZ.
Identifying neurobiological biomarkers with trans-
lational parallels in patients and rodent models is a 
major objective in psychiatric drug discovery. For ScZ 
the greatest progress has arguably been made for cog-
nitive symptoms.7–9 Developing translatable tests for 
positive and negative symptoms is more challenging. 
Prepulse inhibition (PPI) is widely promoted as a cross-
species measure recruiting similar neural circuitry and re-
flecting neural domains involved in positive and cognitive 
symptoms.10,11 Impaired PPI is robustly observed in ScZ 
and correlates with positive symptomatology.12–15 Other 
rodent behaviors deemed relevant to positive symptoms 
include hyperlocomotion, potentially indicative of dopa-
minergic hyperfunction.11 Although the translational rel-
evance of hyperlocomotion is debated, it is influenced by 
ScZ risk genes16,17 and is present in patients.18
ScZ patients exhibit a characteristic pattern of  brain 
imaging (functional and structural) and neurochemical 
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abnormalities. In chronic ScZ functional abnormalities 
include reduced PFC activity (hypofrontality).19,20 
However, during acute psychosis patients show a dif-
ferent profile with elevated ventral striatum (nucleus 
accumbens) and hippocampus/temporal cortex ac-
tivity.21–23 Hippocampal/temporal cortex hyperactivity 
is also seen in chronic ScZ and in those at high risk of 
psychosis.24 Many studies have characterized alterations 
in functional brain network and regional connectivity in 
ScZ, with complex and contradictory findings. In general 
these studies support enhanced functional connectivity, 
potentially limited to specific neural systems, during 
early stages of  the disorder25–28 with a contrasting reduc-
tion in connectivity in chronic ScZ.29–31 Dysconnectivity 
in ScZ may be both disease time-course and neural 
system dependent. For example, with regard to neural 
systems, increased accumbens-PFC,32,33 reduced ventral 
tegmental area (VTA)–thalamus,34 reduced VTA–in-
sular cortex,35 and increased hippocampal–PFC con-
nectivity36 have been reported. Equivalent phenotypes 
are rarely studied in rodent models. However, we have 
shown hypofrontality in rats following subchronic 
NMDA-R antagonist administration37,38 and in mice 
with truncated Disc1.39 These models also show brain 
network connectivity alterations relevant to ScZ.38–40 
These phenotypes provide mechanistic insight and offer 
translational biomarkers against which the efficacy of 
novel therapeutics can be tested.41
Evidence supports both glutamatergic and monoa-
mine (dopamine, serotonin, and noradrenaline) system 
dysfunction in ScZ,42–45 with glutamatergic/NMDA-R 
hypofunction and monoamine hyperfunction, particu-
larly for dopamine, supported. These disturbances have 
also been linked to the dysfunction of ScZ risk genes, 
including Disc1.39,46 Characterizing cerebral metabolic 
responses to drugs that challenge these systems provides 
insight into their in vivo function and the mechanisms by 
which ScZ risk genes mediate their effect.
Here we test the hypothesis that Map2k7+/− mice ex-
hibit alterations in cerebral metabolism and functional 
brain network connectivity relevant to ScZ. To eluci-
date the impact of Map2k7 haploinsufficiency on in vivo 
NMDA-R/glutamate and monoamine system function 
we characterize the cerebral metabolic response to keta-
mine and dextroamphetamine (d-amphetamine), drugs 
that induce ScZ-like symptoms in humans. In light of 
the results obtained, we also characterize the impact of 
d-amphetamine and ketamine on PPI and locomotor ac-
tivity (LMA) in Map2k7+/− mice.
Methods
Animals
Mice heterozygous for Map2k7 (Map2k7+/−) were 
produced as previously described47 and backcrossed onto 
the C57BL/6 background.6 Animals were house under 
standard conditions (21oC, 45%–65% humidity) with a 
12-hour light/dark cycle (lights on 08:00). Experiments 
were conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986.
14C-2-Deoxyglucose Functional Brain Imaging
14C-2-Deoxyglucose (14C-2-DG) brain imaging was 
completed in Map2k7+/− and wild-type (WT) littermate 
mice as previously described.39,48 Alterations in local cere-
bral glucose utilization (LCGU) in brain regions of interest 
(RoI) were analyzed using ANOVA with sex and genotype 
as independent variables. Significance was set at P < .05.
Cerebral Metabolic Responses to d-amphetamine and 
Ketamine
Map2k7+/− and WT mice were challenged with d-
amphetamine (5 mg/kg, intraperitoneally (i.p.), WT: male 
n = 5, female n = 6; Map2k7+/−: male, n = 5; female n = 6) 
or ketamine (25mg/kg, i.p., WT: male n = 4, female n = 4; 
Map2k7+/−: male, n = 5; female n = 5) in physiological sa-
line (2 ml/kg) and underwent the 14C-2-DG protocol.39,49 
In accordance with published protocols14C-2DG was 
injected 1 minute after ketamine and 15 minutes after d-
amphetamine.39,49,50 Control animals received saline (i.p., 
WT: male n = 8, female n = 10; Map2k7+/−: male n = 5; fe-
male n = 7) either 1 minute or 15 minutes before 14C-2-DG 
(50% sample for each time). Data were analyzed using 
ANOVA with sex, genotype and treatment as independent 
variables. Significance was set at P < .05.
Functional Brain Network Analysis
Brain network properties were determined through anal-
ysis of the data from saline-treated animals. Global brain 
network properties, including mean degree (<k>), the 
clustering coefficient (Cp) and average path length (Lp) 
were determined as previously described.39,40,48 Regional 
importance was defined through centrality analysis 
(degree [Ki], betweenness [Bi], closeness [Ci], and ei-
genvector centrality [Ei]) as previously described.
39,40,48 
The standardized z-score centrality measure for each 
RoI was calculated by comparison to 11 000 calibrated 
Erdös−Rényi networks. The significance of the z-score 
difference between experimental groups was determined 
by comparison to 55 000 random permutations  of the 
data. Significance was set a P < .05. A composite z-score, 
across all centrality measures, was also determined with a 
difference >1.96 or < −1.96 considered significant. A de-
tailed overview of the network analysis approaches used 
is included in the supplementary material.
Analysis of Regional Functional Connectivity
Regional functional connectivity was analyzed using 
partial least squares regression (PLSR) as previously 
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described38,39 using the PLS package51 in R (R Core 
Team, 2018). “Seed” region connectivity to all other 
RoI (57) was defined by the variable importance to the 
projection (VIP) statistic. The VIP, SD, and confidence 
interval (CI) were estimated by jack-knifing. A signifi-
cant connection between regions exist if  the 95% CI of 
the VIP statistic >0.8.52 Genotype-induced alterations 
in the VIP statistic were statistically determined by 
the standardized z-score (z-score > 1.96 or < −1.96 
considered significant).
Prepulse Inhibition
PPI was measured in SR-LAB chambers (San Diego 
Instruments) as previously described.53 The impact 
of  5 mg/kg d-amphetamine i.p. (WT: male n = 11, fe-
male n = 6; Map2k7+/−: male n = 11, female n = 12) and 
25 mg/kg ketamine i.p. (WT: male n = 5, female n = 4; 
Map2k7+/−: male n = 3, female n = 4) on % PPI was de-
termined, as these doses disrupt PPI in WT mice.54,55 
Drug and vehicle treatment were counterbalanced 
across days in each experiment. Thereafter % PPI was 
calculated [(startle reactivity at 120 dB – startle reac-
tivity with prepulse) / startle reactivity at 120 dB × 100] 
and analyzed by ANOVA with genotype and sex as be-
tween subjects factors, prepulse intensity and treatment 
as within subjects factors and each mouse nested within 
genotype and sex. Pairwise comparisons were made 
using Fisher’s post hoc test.
Locomotor Activity
LMA was monitored in black opaque Perspex XT arenas 
(40 × 40 × 40 cm) lit from below by infrared LEDs. The 
impact of d-amphetamine and ketamine on LMA was de-
termined, with drug and vehicle injection counterbalanced 
across days in each experiment. Each mouse was placed 
in the center of the arena and allowed to explore for 15 
minutes (habituation). Mice were then treated with 3 mg/
kg d-amphetamine i.p. (WT: male n  =  5, female n  =  4; 
Map2k7+/−: male n = 3, female n = 4), 20 mg/kg ketamine 
i.p. (WT: male n = 5, female n = 5; Map2k7+/−: male n = 5, 
female n = 5) or saline and placed in the arena for the test 
period (ketamine, 30 min; d-amphetamine, 60 min). Total 
distance moved (cm) was measured using EthoVision 
XT (Noldus Information Technology) and analyzed by 
ANOVA with genotype, sex and treatment as between 
subjects factors and each mouse nested within genotype 
and sex. Pairwise comparisons were made using Fisher’s 
post hoc test.
Results
Map2k7 Haploinsufficient Mice Show Hippocampal 
and VTA Hypermetabolism and Orbital Cortex 
Hypometabolism
Map2k7+/− mice show hippocampal hypermetabolism, 
with increased LCGU in the dorsal subiculum (VH-
DS, F(1,26)  =  7.78, P  =  .009) and molecular layer (VH-
ML, F(1,26) = 6.59, P = .016) of the ventral hippocampus 
(figure  1). LCGU was also increased in the VTA 
(F(1,26)  =  4.58, P  =  .041) and medial geniculate (MG, 
F(1,26) = 4.25, P = .049) of Map2k7
+/− mice. By contrast, 
LCGU was significantly decreased in the dorsolateral or-
bital cortex (DLO, F(1,26) = 6.06, P = .021) of Map2k7
+/− 
mice. We found no evidence that the impact of Map2k7 
haploinsufficiency on LCGU was influenced by sex. Full 
data shown in supplementary table S1.
Map2k7 Haploinsufficient Mice Show Abnormal 
Functional Brain Network Connectivity Supporting 
Hippocampal and Septum/DB Hyperconnectivity and 
Mesolimbic Hypoconnectivity
Globally, functional brain networks in Map2k7+/− mice 
had a similar number of  connections (<k>) and showed 
a similar level of  clustering (Cp) to those in WT animals. 
Fig 1. Constitutive LCGU is altered in Map2k7+/− mice. Map2k7+/− mice show dorsolateral orbital cortex (DLO) hypometabolism 
and hippocampal (dorsal subiculum, VH-DS; molecular layer, VH-ML), ventral tegmental area (VTA) and medial geniculate (MG) 
hypermetabolism. Data shown as mean ± standard error of the mean. *P < .05, **P < .01 genotype effect (ANOVA).
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However, average path length (Lp) is significantly reduced 
(P = .0123) in Map2k7+/− mice (figure 2), supporting an 
altered network structure that promotes more efficient 
information transfer across brain networks in these 
animals.
Multiple hippocampal subfields were identified as 
having significantly greater centrality in Map2k7+/− 
mice (table 1). Multiple regions of  the septum/diagonal 
band of  Broca (septum/DB) and amygdala, along with 
the dorsal reticular thalamus (dRT) and multiple PFC 
subfields, were also identified as having increased cen-
trality in Map2k7+/− mice. These findings support the 
hyperconnectivity of  these neural systems in Map2k7+/− 
mice, that contributes to the global hyperconnectivity 
(decreased Lp, figure 2) seen in these animals. Significant 
decreases in centrality in Map2k7+/− mice were also 
identified, limited to the mesolimbic system and 
retrosplenial cortex (RSC, table 1). Full centrality data 
shown in supplementary table S2.
PLSR Analysis Further Identifies Altered Prefrontal–
Thalamic–Hippocampal, Septum/DB-Hippocampal and 
Mesolimbic System Connectivity in Map2K7+/− Mice
PLSR analysis revealed prefrontal–thalamic–hippocampal 
and septum/DB–hippocampal hyperconnectivity, along 
with mesolimbic system hypoconnectivity, in Map2k7+/− 
mice (figure 2) mirroring the alterations found by centrality 
analysis (table 1).
When the ventral hippocampus DS and ML were 
considered as seed regions there was evidence that the 
connectivity of  the septum/DB, which provides di-
rect innervation to the hippocampus,56 was abnormally 
increased in Map2k7+/− mice (figure 2), consistent with 
the increased centrality of  these regions in these an-
imals. The connectivity of  DS and ML to the medial 
PFC (infralimbic cortex, IL) was also significantly 
increased in Map2k7+/− mice. There was also evidence 
for enhanced connectivity between hippocampal 
subfields in Map2k7+/− mice, specifically for the DS, a 
primary output of  the hippocampus.57 Other abnormal 
DS and ML connectivity in Map2k7+/−mice included 
increased connectivity to the thalamus (anteromedial 
nucleus [AM], centomedial nucleus [CM], ventromedial 
nucleus  [VM], nucleus reuniens  [Re]), auditory system 
(auditory cortex [AudC], medial geniculate [MG], infe-
rior colliculus  [IC]) and the serotonergic dorsal raphé 
(DR). In contrast to these broad increases in con-
nectivity, selective losses in DS and ML connectivity 
were also found, including lost connectivity to the 
mesolimbic system (nucleus accumbens core [NaC], nu-
cleus accumbens shell  [NaS]) and RSC, mirroring the 
decreased centrality of  these regions (table 1).
When the DLO was considered as the seed region 
abnormal functional connectivity between this PFC 
subfield and the hippocampus (DH-CA1, DH-CA2, 
VH-CA2) was found in Map2k7+/− mice. In addition, the 
DLO showed abnormal functional connectivity to the 
mesolimbic system (VTA and NaS) in Map2k7+/− mice. 
By contrast, connectivity of  the DLO to its projecting 
thalamic nuclei (AM, anteroventral nucleus  [AV], 
mediodorsal nucleus [MD]) was lost in Map2k7+/− mice.
When the VTA was considered as the seed, lost con-
nectivity to other mesolimbic regions (NaS), the basal 
ganglia (dorsolateral striatum  [DLST], globus pal-
lidus [GP], substantia nigra pars compacta [SNC]) and 
thalamic nuclei (AM, AV, ventrolateral nucleus  [VL], 
dRT) was found in Map2k7+/− mice. Significant increases 
in VTA connectivity in Map2k7+/− mice were limited. 
However, new abnormal connectivity between the DR 
and VTA was found, suggesting that serotonergic reg-
ulation of  the VTA may be altered in Map2k7+/− mice 
(figure 2).
MG functional connectivity was also altered in 
Map2k7+/− mice, including increased connectivity to the 
mesolimbic system (NaC and NaS) and lost connectivity 
to the basal ganglia (DLST, GP, SNR) and thalamic nu-
clei (dRT, CM and VL).
Full PLSR data are included in supplementary tables 
S3–S7.
The Cerebral Metabolic Response to Ketamine Is Not 
Altered in Map2K7+/− Mice
In accordance with published data subanesthetic keta-
mine increased LCGU in the PFC, hippocampus and 
nucleus accumbens and induced hypometabolism in the 
reticular thalamus and selected neuromodulatory nu-
clei.39,49 We found no evidence that the response to ke-
tamine was significantly altered in Map2k7+/− mice 
(figure 3). This suggests that NMDA-R/glutamate system 
function is not significantly disrupted in Map2k7+/− mice. 
Full data are shown in supplementary table S8.
The Cerebral Metabolic Response to d-amphetamine Is 
Reduced in Map2K7+/− Mice
In accordance with published data d-amphetamine 
increased LCGU in the thalamus, hippocampus, PFC, 
and basal ganglia in WT mice.50,58 d-amphetamine also 
increased LCGU in neuromodulatory nuclei including 
the raphé (DR; median, MR) and locus coeruleus (LC), 
while decreasing LCGU in the amygdala.
We found widespread evidence that the LCGU response 
to d-amphetamine was attenuated in Map2k7+/− mice. 
This included a significantly reduced LCGU response in 
multiple PFC (aPrL, DLO, ventral orbital  [VO], medial 
orbital [MO], cingulate [Cg1]), thalamic (AM, AV, MD, 
VM, dRT), and hippocampal (DH-ML, VH-DS) regions 
(figure 4). These effects were supported by significant gen-
otype × treatment interaction in each RoI (ANOVA) and 
confirmed by post hoc testing (Tukey’s honestly signifi-
cant difference [HSD]). For two brain regions the impact 
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Fig. 2. Map2k7+/− mice show altered functional brain network connectivity. (a) Average path length (Lp) is decreased (P = .012) whereas 
mean degree (<k>) and clustering (Cp) are not altered in Map2k7
+/− mice. (b) Heatmaps showing altered inter-regional connectivity 
in Map2k7+/− mice. Red denotes gained (ventral tegmental area [VIP] 95% CI >0.8 in Mapk7+/−, <0.8 in wild-type [WT] and z-score 
difference >1.96) and blue denotes lost (VIP 95% CI >0.8 in WT, <0.8 in Map2k7+/− and z-score difference <−1.96) connectivity in 
Map2k7+/− mice. PFC = prefrontal cortex, HP = hippocampus, Mesol. = mesolimbic system, Sept/DB = septal/diagonal band of Broca, 
Ctx = cortex, BG = basal ganglia, Aud. = auditory system, Nm = neuromodulatory nuclei, Multi. = multimodal. Full connectivity 
heatmaps are shown in supplementary figure S2. (c) Brain images showing the anatomical localization of altered inter-regional 
connectivity in Map2k7+/− mice. Blue denotes lost and red denotes gained connectivity. Brain sections modified from the Allen atlas 
(mouse.brain-map.org/static/atlas).
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of Map2k7 heterozygosity on the LCGU response to 
d-amphetamine was found to be more pronounced in 
females than in males. In this way a significant sex × 
genotype × treatment interaction was found in the RSC 
(F(1,44) = 5.08, P = .029) and VTA (F(1,44) = 5.52, P = .023). 
When each sex was analyzed separately a significant gen-
otype × treatment interaction was identified in females 
(RSC, F(1,25) = 13.52, P = .001; VTA, F(1,25) = 18.73, P < 
.001) but not in males (RSC, F(1,19) = 0.33, P = .574, VTA, 
F(1,19) = 0.530, P = .476). Post hoc analysis in females con-
firmed that while d-amphetamine significantly increased 
LCGU in WT animals (RSC, P < .001; VTA, P < .001; 
Tukey’s HSD) the drug had no effect in Map2k7+/− mice 
(RSC, P = .434, VTA, P = .919). Full data are shown in 
supplementary table S9.
Male Map2k7+/− Mice Show a PPI Deficit and 
Attenuated Responses to d-amphetamine
As d-amphetamine disrupts PPI and induces 
hyperlocomotion59,60 we assessed behavioral sensitivity 
to d-amphetamine in Map2k7+/− mice. Sex-dependent 
effects were observed, whereby male Map2k7+/− mice 
showed reduced baseline PPI relative to WT males, with 
no baseline genotype difference in females (figures 5a and 
5b). d-amphetamine significantly reduced PPI in WT 
Table 1. Alterations in Regional Centrality in Map2k7+/− Mice 
Brain Region Degree (Ki) Betweenness (Bi) Closeness (Ci) Eigenvector (Ei)
Composite 
Z-score
Increased centrality
 Prefrontal cortex
  aPrL 2.34 3.14 3.79 2.64 2.98
  DLO 1.71 7.21 3.72 0.80 3.36
  IL 0.29 2.40 6.79* 3.00* 3.12
 Septum/diagonal band of broca
  MS 2.51 3.15 7.05* 5.72* 4.61
  LS 2.28 3.08 7.12* 5.69* 4.54
  HDB 2.18 1.83 7.30* 3.29* 3.65
 Hippocampus
  DH-CA1 1.01 0.68 5.13 6.21* 3.26
  DH-CA2 1.29 0.33 5.35 6.08* 3.26
  DH-DG 0.62 −1.15 4.43 5.94* 2.46
  VH-CA1 2.05 −1.23 3.68 5.85* 2.59
  VH-CA2 1.51 0.44 3.86 5.44* 2.81
  VH-CA3 1.24 1.14 4.71 6.23* 3.33
  VH-DG 0.73 0.92 4.24 5.77* 2.91
 Amygdala
  BLA 1.87 1.74 5.61 5.78* 3.75
  MeA 0.76 −0.08 3.57 4.91* 2.29
 Thalamus
  dRT 1.15 5.12 5.84* −0.36 2.94
Decreased centrality
 Mesolimbic system
  NaC −3.06 −14.54* −2.68 0.15 −5.03
  NaS −0.20 −5.31 −2.72 −0.02 −2.06
  VTA −1.60 −0.92 −1.10 −4.26 −1.97
 Cortex
  RSC −1.21 −5.53 0.20 −3.46 −2.50
  Piri −1.85 −14.89* −1.33 −3.70 −5.44
  FRA −2.72 −3.80 0.07 −2.58 −2.26
Note: aPrL, anterior prelimbic cortex; DLO, dorsolateral orbital cortex; IL, infralimbic cortex; MS, medial septum; LS, lateral septum; 
HDB, horizontal limb of the diagonal band of Broca; DH-CA1, dorsal hippocampus cornu ammonis 1; DH-CA2, dorsal hippocampus 
cornu ammonis 2; DH-DG, dorsal hippocampus dentate gyrus; VH-CA1; ventral hippocampus cornu ammonis 1; VH-CA2, ventral 
hippocampus cornu ammonis 2; VH-CA3, ventral hippocampus cornu ammonis 3, VH-DG, ventral hippocampus dentate gyrus; BLA, 
basolateral amygdala; MeA, medial amygdala; dRT, dorsal reticular thalamus, NaC, nucleus accumbens core; NaS, nucleus accumbens 
shell; VTA, ventral tegmental area; RSC, retrosplenial cortex; Piri, piriform cortex, FRA, frontal association cortex.
*denotes P < .05 significant difference from WT (55 000 random permutations of the real data) within the given centrality measure. 
A composite standardized z-score was also calculated across all centrality measures. A composite z-score > 1.96 or < −1.96 was 
considered to be significant. Positive z-scores indicate an increase in regional centrality in Map2k7+/−mice relative to WT controls, and 
negative z-scores indicate a decrease in centrality in Map2k7+/−mice relative to controls. Only regions with a significant composite z-score 
are shown. Full centrality data shown in supplementary table S4.
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male but not WT female mice (figures 5a and 5b), limiting 
the detection of an attenuated d-amphetamine response 
in female Map2k7+/− mice. Nevertheless, the impact of d-
amphetamine on PPI was significantly attenuated in male 
Map2k7+/− mice (figure  5a), and remained significant 
when data from both sexes was pooled (figures  5c and 
5f). In parallel, d-amphetamine’s stimulatory effects on 
LMA was significantly attenuated in male (F(1,353) = 1763, 
P < .001) but not female Map2k7+/− mice (figure 5j).
Map2k7+/− Mice Show Hyperlocomotion and Preserved 
Behavioral Responses to Ketamine
As LCGU responses to ketamine were unaltered in 
Map2k7+/− mice (figure 3), we tested if  this was evident 
behaviorally by characterizing ketamine’s impact on PPI 
and LMA.61,62 Consistent with brain imaging data the im-
pact of ketamine on PPI (F(1,95) = 111.30, P < .001) was 
not attenuated in Map2k7+/− mice (F(1,95) = 0.01, P = .92, 
figures  5d and 5e). Comparable results were obtained 
when measuring LMA where ketamine induced hyperac-
tivity in both WT and Map2k7+/− mice (F(1,359) = 54.5, P 
< .001, figure 5i). Although Map2k7+/− mice were signifi-
cantly hyperactive relative to WT (F(1,359) = 10.9, P = .001, 
figure  5h) there was no difference in the magnitude of 
the ketamine response between Map2k7+/− and WT mice 
(P = .457, figure 5i).
Discussion
Map2k7+/− mice show brain imaging endophenotypes 
and behavioral phenotypes relevant to ScZ. Behaviorally 
this includes a deficit in sensorimotor gating and 
hyperlocomotor activity, relevant to the positive 
symptoms of ScZ.12–15 Previous studies have identified 
cognitive and reward processing deficits in Map2k7+/− 
mice, also relevant to ScZ.3,6 The brain metabolism and 
network connectivity deficits identified in Map2k7+/− 
mice align with these behavioral deficits. Moreover, 
Map2k7+/− mice show altered cerebral metabolism and be-
havioral responses to d-amphetamine but not ketamine, 
supporting monoaminergic system but not NMDA-R/glu-
tamate system dysfunction as a consequence of Map2k7 
haploinsufficiency.
The endophenotype concept continues to evolve in psy-
chiatric genetics.63–65 Key features include the following: 
(1) heritability and cosegregation with a disorder, or with 
a symptom domain that may cross diagnostic boundaries. 
Evidence for the association of MAP2K7 gene variants 
that result in decreased MAP2K7 expression with ScZ3 
Fig 3. The LCGU response to ketamine is not altered in Map2k7+/− mice. Data shown as mean ± standard error of the mean. ***P < 
.001 effect of ketamine (ANOVA).
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supports the construct validity of Map2k7+/− mice. (2) 
The endophenotype being part of the biological disease 
process (eg, functional or structural brain changes) and 
relating to the symptoms of the disease. We discuss below 
the strong translational alignment between the imaging 
endophenotypes and behavioral deficits identified in 
Map2k7+/− mice and those seen in ScZ. We also discuss 
the alignment of the imaging endophenotypes seen in 
these animals with their behavioral deficits.
Map2k7+/− Mice Show ScZ-Relevant Alterations in 
Cerebral Metabolism and Brain Network Connectivity
The alterations in LCGU identified in Map2k7+/− mice 
parallel those observed in ScZ. This includes DLO 
hypometabolism and hippocampal hypermetabolism, 
mirroring orbitofrontal hypometabolism19,66 and 
hippocampal/temporoparietal hypermetabolism in 
ScZ.21–24 Intriguingly, we have previously identified DLO 
hypometabolism in genetic39 and pharmacological38 ro-
dent models relevant to the disorder. The alterations 
in functional brain network connectivity present in 
Map2k7+/− mice also parallel those in ScZ. Although the 
decreased path length (figure  2) and increased regional 
centrality (table 1) in Map2k7+/− mice contrasts with that 
reported in chronic ScZ,29–31 it does parallel the increased 
connectivity seen in first episode psychosis,26 patients 
with prominent auditory hallucinations21 and those 
with childhood onset ScZ.28 Increased global efficiency 
of brain network connectivity has also been reported in 
chronic ScZ.67 We also found evidence for increased PFC 
connectivity in Map2k7+/− mice, paralleling that reported 
in early but not chronic ScZ and in those at high risk of 
developing the disorder.25 Increased PFC connectivity is 
also found after ketamine administration,25,48,49 a trans-
lational model relevant to ScZ, and is present in other 
genetic mouse models.39 This suggests that specific neural 
systems, such as the PFC, may show increased connec-
tivity at early disease stages or in those at risk of devel-
oping ScZ, and that Map2k7+/− mice may have particular 
translational relevance to these populations.
Alterations in inter-regional connectivity in Map2k7+/− 
mice also have relevance to those in ScZ. This includes 
increased PFC-accumbens,32,33 reduced VTA-thalamus,34 
reduced VTA-insular cortex,35 and abnormal hippocampal 
connectivity. Increased hippocampal–PFC connectivity in 
Fig 4. The LCGU response to d-amphetamine is attenuated in Map2k7+/− mice. Data shown as mean ± standard error of the mean. 
#P < .05, ##P < .01 genotype × treatment (ANOVA). **P < .01, ***P < .001 d-amphetamine effect within genotype (Tukey’s honestly 
significant difference [HSD]). +P < .05 difference from wild-type (WT) within same treatment (Tukey’s HSD). Significant sex × genotype 
× treatment interactions in retrosplenial cortex (RSC) (F(1,44)=5.08, P = .029) and VTA (F(1,44)=5.52, P = .023). 
‡‡P < .01 genotype × 
treatment interaction within sex (ANOVA). †††P<.001 d-amphetamine effect within sex (ANOVA).
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Fig 5. Analysis of Map2k7+/− mice in behavioral assays relevant to positive symptomatology. PPI in (a) male and (b) female mice 
following saline or d-amphetamine (5 mg/kg). Males: effect of d-amphetamine (F(1,131) = 14.34, P < .001) and genotype × d-amphetamine 
(F(1,131) = 14.45, P < .001). Females: no significant effect of d-amphetamine or d-amphetamine × genotype. ** P < .01, *** P < .001 
treatment effect (Fisher’s post hoc), ++ P < .01 genotype effect. Mean decrement in PPI (vehicle – d-amphetamine) for sex-pooled data (c) 
separated stimulus dB and (f) pooled dBs. * P < .05 genotype effect ((c) ANOVA, (f) Kruskal–Wallis). (d, e, and g) Ketamine effects on 
PPI (F(1,95) = 11.30, P < .001) shown as % PPI for pooled-sex mice (d) effect of ketamine (F(1,95) = 11.05, P = .002), genotype × ketamine 
P = .92. **P < .01 genotype effect. Mean decrement in PPI (vehicle – ketamine) for pooled-sex mice, (e) separated stimulus dB and 
(g) pooled dBs. (h) Basal LMA during habituation (15 min) and after saline administration (30 min). Map2k7+/− mice showed elevated 
LMA relative to wild-type (WT) (F(1,39) = 8.3, P = .01). (i) Ketamine (20 mg/kg) induced hyperactivity in both WT and Map2k7
+/− mice 
(F(1,359) = 54.5, P < .001). (j) d-amphetamine (3 mg/kg) also induced hyperactivity (F(1,353) = 1763, P < .001, pooled sex), which was 
significantly attenuated in male Map2k7+/− mice relative to male WTs (**P < .01, Tukey’s post hoc).
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non-medicated ScZ patients36 and those with pronounced 
auditory hallucinations33 has been reported, as has increased 
default mode network connectivity in those at risk of de-
veloping psychosis.68 Studies have reported regional speci-
ficity in the altered hippocampal–PFC connectivity present 
in patients, and whether increases or decreases in connec-
tivity are found.36,69 There may be a genetic basis to these 
divergent observations as both increased (ZNF804A)70 and 
decreased (Disc139; 22q11.271) hippocampal–PFC connec-
tivity are reported in risk gene mouse models. Many of the 
functional connectivity alterations present in Map2k7+/− 
mice are predictive of antipsychotic response in patients, 
including alterations in hippocampal–PFC,72 VTA–thal-
amus,34 and PFC–accumbens connectivity,34,72 suggesting 
that these may provide translational biomarkers against 
which the efficacy of novel antipsychotics can be tested in 
Map2k7+/− mice.
Brain Imaging Endophenotypes in Map2k7+/− Mice 
Align With Their Translational Behavioral Deficits
Map2k7+/- mice show a deficit in PFC-dependent 
working memory3,6 and, in this study, hypofrontality 
(figure 1). As MAP2K7 expression levels are decreased 
in the PFC in ScZ3 and Map2k7 modulates PFC-
dependent cognitive processes and metabolism, Map2k7 
dysfunction may contribute to the hypofrontality19 and 
working memory deficits73 seen in ScZ. In addition, 
Map2k7+/− mice show altered reward processing6 that 
may relate to their altered mesolimbic system function 
(figures 1 and 2). In humans, mesolimbic system con-
nectivity is linked to trait anhedonia74 suggesting that 
the mesolimbic dysconnectivity and reward processing 
deficits seen in Map2k7+/− mice may have relevance to 
the anhedonia and altered reward processing present in 
patients.75,76
We detected reduced PPI in male, but not female, 
Map2k7+/−mice. Impaired PPI is reliably observed in ScZ, 
may be more pronounced in male patients,77 and correlates 
with positive symptoms.12–15 PPI is a multisystem phe-
nomenon, involving many brain regions including the 
RT, MD, PFC, and hippocampus,78 systems found to be 
dysfunctional in Map2k7+/− mice.
Altered Septal–Hippocampal Connectivity in 
Map2k7+/− Mice May Contribute to Their Altered 
Response to d-amphetamine
Map2k7+/− mice show increased septum/DB–
hippocampal connectivity (table 1, figure 2). The septum/
DB regulates hippocampal activity, including the  regu-
lation of hippocampal theta waves.79,80 These waves are 
dysfunctional in ScZ, modulate hippocampal–PFC con-
nectivity81 and are influenced by other ScZ risk genes.70 
The septum also modulates VTA dopaminergic neuron 
activity via the hippocampus and influences the response 
to amphetamine.82 Intriguingly, we found increased 
hippocampal and VTA activity in Map2k+/− mice 
(figure 1), suggesting that increased septal–hippocampal 
connectivity (figure 2) may drive increased hippocampal-
VTA circuit activity in these animals. Previous studies 
have shown that lesioning83 or modulating activity in the 
septum84 alters the response to amphetamine. Given the 
key role of the septo-hippocampal pathway in PPI,85 and 
that the impact of d-amphetamine on hippocampal and 
VTA activity is attenuated in Map2k7+/− mice (figure 4), 
dysfunction in this circuitry may contribute to the 
baseline PPI deficits and the attenuated impact of d-
amphetamine on PPI in Map2k7+/− mice. Intriguingly, 
the impact of amphetamine on cerebral metabolism and 
PFC dopamine release is attenuated in ScZ, mirroring the 
observations in Map2k7+/− mice.86,87
Overall, the data suggest that Map2k7+/− mice display 
a range of  brain imaging and behavioral deficits that 
have translational relevance to ScZ. The dysfunction 
appears to be relevant to a broad range of  ScZ symptoms, 
against which the efficacy of  novel therapeutics can be 
tested. Brain imaging endophenotypes in these ani-
mals with translational relevance to positive symptoms 
may be particularly useful because of  the paucity and 
ambiguity of  current behavioral phenotypes for these 
symptoms.
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